source
- Rezera delays $200M IPO amid weak market conditionsRezera, a biotech developing drugs for cardiovascular and inflammatory diseases, announced that it will not proceed with its planned initial public offering that had been scheduled for Friday. The…
- FDA shelves Commissioner’s National Priority Voucher program ahead of Heidi Overton confirmation voteThe Food and Drug Administration has halted the Commissioner’s National Priority Voucher (CNPV) program as the Senate prepares to vote on Heidi Overton’s nomination as the agency’s next commissione…